Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.65 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.65 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.65 |
| ▸ | GCGR | P47871 | 1/20 | 0.65 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1387188 | 1.00 | MAPK14 (0.65) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL7503500 | 0.90 | MAPK14 (0.52) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL6695860 | 0.90 | MAPK14 (0.52) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL19864312 | 0.82 | MAPK14 (0.73) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL1387186 | 0.81 | MAPK14 (0.71) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL1387412 | 0.79 | MAPK14 (1.00) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL19868953 | 0.76 | MAPK14 (0.64) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| SCHEMBL9025437 | 0.76 | PTGS2 (0.45) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| Sb-203580 SCHEMBL146399 | 0.76 | MAPK11 (0.75) | MAPK14MAPK11MAPK13GCGRMAPK12 | |
| Sb-203580 SCHEMBL95208 | 0.76 | MAPK11 (0.75) | MAPK14MAPK11MAPK13GCGRMAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102207-B1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY SCIENCE TECH & RES (SG) | 2022-05-11 | — | — | EP | disclosed |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-15 | — | — | US | disclosed |
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2020-12-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2017-06-15 | — | — | US | disclosed |
| EP-3102207-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | Agency For Science, Technology And Research (SG) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015119579-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10865384-B2 | 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK14 241/4885MAPK11 372/4885MAPK13 234/4885 |
| US-20170166867-A1 | 2,4,5-TRI-SUBSTITUTED AZOLE-BASED CASEIN KINASE 1 INHIBITORS AS INDUCERS FOR CARDIOMYOGENESIS | CSNK1A1, CSNK1G1, CSNK2A1 | MAPK14 241/4885MAPK11 372/4885MAPK13 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.